Finance

Beta
Lists
NTLA:NASDAQ
Intellia Therapeutics Inc
$16.03
+3.42%
(+0.53) 1D
$15.80
-1.43% (-0.23)
After hours
Closed: Jun 25, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NTLA...
Open
$15.62
High
$16.26
Low
$15.58
Mkt. cap
2.24B
Avg. vol.
6.81M
Volume
3.47M
52-wk high
$28.24
52-wk low
$7.95
EPS
-$3.53
Beta
1.92
Shares outstanding
139.72M
No. of employees
377
Open
$15.62
High
$16.26
Low
$15.58
Mkt. cap
2.24B
Avg. vol.
6.81M
Volume
3.47M
52-wk high
$28.24
52-wk low
$7.95
EPS
-$3.53
Beta
1.92
Shares outstanding
139.72M
No. of employees
377
News stories
From sources across the web
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees377
Founded2014
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websiteintelliatx.com
Analyst ratings
Based on 18 analysts giving stock ratings to NTLA in the past 3 months
Buy
Buy
8
Hold
8
Sell
2
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for NTLA in the last 3 months.
Highest
Current $16.03
$49.00 (+205.68%)
Average
$21.06 (+31.38%)
Lowest
$8.00 (-50.09%)
Analyst
Recommendation
Action
Price target
Projected
Date
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$49.00
+205.7%
06/16/2026
Alec Stranahan
Bank of America Securities
Hold
Maintained
$19.00
+18.5%
06/15/2026
Salveen Richter
Goldman Sachs
Sell
Maintained
$9.00
-43.9%
06/14/2026
Unknown Analyst
Wedbush
Hold
Maintained
$12.00
-25.1%
06/15/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
06/14/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$25.00
+56%
06/15/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
06/15/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$29.00
+80.9%
05/27/2026
Brian Cheng
J.P. Morgan
Sell
Maintained
$8.00
-50.1%
05/13/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
$15.00
-6.4%
05/13/2026
William Pickering
Bernstein
Hold
Reiterated
$17.00
+6.1%
05/13/2026
Yanan Zhu
Wells Fargo
Hold
Maintained
$15.00
-6.4%
05/12/2026
Luca Issi
RBC Capital
Hold
Maintained
$15.00
-6.4%
05/11/2026
Jonathan Miller
Evercore ISI
Hold
Maintained
$16.00
-0.2%
04/28/2026
Silvan Tuerkcan
Citizens JMP
Buy
Maintained
$30.00
+87.1%
04/28/2026
Geulah Livshits
Chardan Capital
Buy
Maintained
$30.00
+87.1%
04/27/2026
Mani Foroohar
Leerink Partners
Buy
Reiterated
$35.00
+118.3%
04/27/2026
Jack Allen
Robert W. Baird
Hold
Maintained
$13.00
-18.9%
04/27/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
03/02/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
14.24M
13.78M
23.02M
15.05M
Cost of goods sold
80.53M
78.95M
73.63M
80.74M
Cost of revenue
80.53M
78.95M
73.63M
80.74M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
43.71M
46.31M
48.10M
34.84M
Operating expense
43.71M
46.31M
48.10M
34.84M
Total operating expenses
124.24M
125.26M
121.73M
115.58M
Operating income
-110.00M
-111.48M
-98.71M
-100.53M
Other non operating income
-
-
-
-
EBT including unusual items
-101.26M
-101.32M
-95.79M
-96.23M
EBT excluding unusual items
-102.59M
-104.76M
-92.23M
-95.33M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-101.26M
-101.32M
-95.79M
-96.23M
Net profit margin
-710.81%
-735.19%
-416.15%
-639.49%
Earnings per share
-0.98
-0.92
-0.83
-0.81
Interest and investment income
7.40M
6.71M
6.48M
5.20M
Interest expense
-
-
-
-
Net interest expenses
7.40M
6.71M
6.48M
5.20M
Depreciation and amortization charges
-
-
-
-
EBITDA
-107.52M
-109.06M
-96.33M
-98.33M
Gain or loss from assets sale
-
-
527.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of NTLA
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer